Skip to main content

Table 2 Clinical characteristics of pregabalin abuse among the studied group

From: Some psychiatric comorbidity among patients with substance abuse disorder related to pregabalin

Variable

(n = 83)

No.

%

Duration (months)

Median (IQR)

24 (12–36)

Start dose (mg)

Median (IQR)

300 (150–750)

Maximum dose (mg)

Median (IQR)

1500 (750–1500)

Daily dose (mg)

Median (IQR)

1500 (750–1500)

Last dose since (day)

Median (IQR)

15 (4–30)

Course

Continuous

72

86.7

Intermittent

11

13.3

Type of addiction

Mono

17

20.5

79.5

Poly

66

Causes of abuse

Replacement of heroin

49

59

Due to pain

40

48.2

Replacement of tramadol

26

31.3

For its euphoric and analgesic effect

8

9.6

Causes of seeking treatment

Family causes

67

80.7

Medical causes

14

16.9

Economic causes

2

2.4

Urine test

−ve

60

72.3

+ve

23

27.7

  1. IQR interquartile range